TY - JOUR
T1 - The need to incorporate aged animals into the preclinical modeling of neurological conditions
AU - Sun, Mujun
AU - McDonald, Stuart J.
AU - Brady, Rhys D.
AU - Collins-Praino, Lyndsey
AU - Yamakawa, Glenn R.
AU - Monif, Mastura
AU - O'Brien, Terence J.
AU - Cloud, Geoffrey C.
AU - Sobey, Christopher G.
AU - Mychasiuk, Richelle
AU - Loane, David J.
AU - Shultz, Sandy R.
PY - 2020/2/1
Y1 - 2020/2/1
N2 - Neurological conditions such as traumatic brain injury, stroke, Parkinson's disease, epilepsy, multiple sclerosis, and Alzheimer's disease are serious clinical problems that affect millions of people worldwide. The majority of clinical trials for these common conditions have failed, and there is a critical need to understand why treatments in preclinical animal models do not translate to patients. Many patients with these conditions are middle-aged or older, however, the majority of preclinical studies have used only young-adult animals. Considering that aging involves biological changes that are relevant to the pathobiology of neurological diseases, the lack of aged subjects in preclinical research could contribute to translational failures. This paper details how aging affects biological processes involved in neurological conditions, and reviews aging research in the context of traumatic brain injury, stroke, Parkinson's disease, epilepsy, multiple sclerosis, and Alzheimer's disease. We conclude that aging is an important, but often overlooked, factor that influences biology and outcomes in neurological conditions, and provide suggestions to improve our understanding and treatment of these diseases in aged patients.
AB - Neurological conditions such as traumatic brain injury, stroke, Parkinson's disease, epilepsy, multiple sclerosis, and Alzheimer's disease are serious clinical problems that affect millions of people worldwide. The majority of clinical trials for these common conditions have failed, and there is a critical need to understand why treatments in preclinical animal models do not translate to patients. Many patients with these conditions are middle-aged or older, however, the majority of preclinical studies have used only young-adult animals. Considering that aging involves biological changes that are relevant to the pathobiology of neurological diseases, the lack of aged subjects in preclinical research could contribute to translational failures. This paper details how aging affects biological processes involved in neurological conditions, and reviews aging research in the context of traumatic brain injury, stroke, Parkinson's disease, epilepsy, multiple sclerosis, and Alzheimer's disease. We conclude that aging is an important, but often overlooked, factor that influences biology and outcomes in neurological conditions, and provide suggestions to improve our understanding and treatment of these diseases in aged patients.
KW - Alzheimer's disease
KW - Cerebrovascular
KW - DNA damage
KW - Epilepsy
KW - Immune response
KW - Mitochondrial function
KW - Multiple sclerosis (MS)
KW - Oxidative stress
KW - Parkinson's disease
KW - Protein dysregulation
KW - Stroke
KW - Traumatic brain injury (TBI)
UR - http://www.scopus.com/inward/record.url?scp=85077394648&partnerID=8YFLogxK
U2 - 10.1016/j.neubiorev.2019.12.027
DO - 10.1016/j.neubiorev.2019.12.027
M3 - Review Article
C2 - 31877345
AN - SCOPUS:85077394648
SN - 0149-7634
VL - 109
SP - 114
EP - 128
JO - Neuroscience and Biobehavioral Reviews
JF - Neuroscience and Biobehavioral Reviews
ER -